Literature DB >> 4018845

Regulation of human natural killing by lysosomotropic and thiol-reactive agents.

H Shau, J R Dawson.   

Abstract

Treatment of human peripheral blood lymphocytes (PBL) with ammonium or other lysosomotropic amines eliminates natural killing (NK) activity of effector cells without affecting their viability. Inhibition of NK by these reagents is probably due to blocking of events subsequent to effector cell target cell binding but before programming for cytolysis. Treatment of K562 target cells with the same reagents has no effect on target cell sensitivity to NK. Pretreatment of effector cells with the NK inhibitory lysosomotropic agents decreases lysosomal thiol cathepsin activity without affecting the lysosomal acid phosphatase activity. Thiol-reactive agents, tosyl-L-lysine chloromethyl ketone (TLCK) and iodoacetamide also inhibit NK and thiol cathepsin activity in PBL. These data suggest a role for thiol-containing enzymes in the early stages of NK cytolysis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4018845      PMCID: PMC1453781     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  A functional comparison of human Fc-receptor-bearing lymphocytes active in natural cytotoxicity and antibody-dependent cellular cytotoxicity.

Authors:  H D Kay; G D Bonnard; W H West; R B Herberman
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

Review 2.  Commentary. Lysosomotropic agents.

Authors:  C de Duve; T de Barsy; B Poole; A Trouet; P Tulkens; F Van Hoof
Journal:  Biochem Pharmacol       Date:  1974-09-15       Impact factor: 5.858

3.  Studies on acid hydrolases in adult and foetal tissues. Acid rho-nitrophenyl phosphate phosphohydrolases of adult guinea-pig liver.

Authors:  M W Neil; M W Horner
Journal:  Biochem J       Date:  1964-07       Impact factor: 3.857

4.  Some characteristics of the alanine aminotransferase- and arginase-inactivating system of lysosomes.

Authors:  M Haider; H L Segal
Journal:  Arch Biochem Biophys       Date:  1972-01       Impact factor: 4.013

5.  Target-effector cell interaction in the natural killer cell system. V. Energy requirements, membrane integrity, and the possible involvement of lysosomal enzymes.

Authors:  J C Roder; S Argov; M Klein; C Petersson; R Kiessling; K Andersson; M Hansson
Journal:  Immunology       Date:  1980-05       Impact factor: 7.397

6.  Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum.

Authors:  D P Beebe; N R Cooper
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

7.  Phospholipid methylation and phospholipase A2 activation in cytotoxicity by human natural killer cells.

Authors:  T Hoffman; F Hirata; P Bougnoux; B A Fraser; R H Goldfarb; R B Herberman; J Axelrod
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

8.  Characteristics of human large granular lymphocytes and relationship to natural killer and K cells.

Authors:  T Timonen; J R Ortaldo; R B Herberman
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

9.  Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling.

Authors:  A Gonzalez-Noriega; J H Grubb; V Talkad; W S Sly
Journal:  J Cell Biol       Date:  1980-06       Impact factor: 10.539

10.  Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1.

Authors:  M Wibo; B Poole
Journal:  J Cell Biol       Date:  1974-11       Impact factor: 10.539

View more
  2 in total

1.  Lysosome rich cells contain the lytic activity of lymphokine-activated killer cell populations.

Authors:  R Agah; H Shau; A Mazumder
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Role of thiols in human peripheral blood natural killer and killer lymphocyte activities.

Authors:  N H Stacey; G K Craig
Journal:  Experientia       Date:  1989-02-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.